181 related articles for article (PubMed ID: 27286996)
41. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Fukuda M; Kitazaki T; Ogawara D; Ichiki M; Mukae H; Maruyama R; Nakagaki N; Shimada M; Ikeda T; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Okamoto I; Ichinose Y; Sugio K
Lung Cancer; 2019 Jun; 132():1-8. PubMed ID: 31097081
[TBL] [Abstract][Full Text] [Related]
42. Incidence of cutaneous reactions with pemetrexed: Comparison of patients who received three days of oral dexamethasone twice daily to patients who did not.
Clark SK; Anselmo LM
J Oncol Pharm Pract; 2019 Oct; 25(7):1645-1650. PubMed ID: 30319062
[TBL] [Abstract][Full Text] [Related]
43. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
44. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
45. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
46. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
47. Safety of dose-reduced pemetrexed in patients with renal insufficiency.
Hill J; Vargo C; Smith M; Streeter J; Carbone DP
J Oncol Pharm Pract; 2019 Jul; 25(5):1125-1129. PubMed ID: 29871545
[TBL] [Abstract][Full Text] [Related]
48. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
49. EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma.
Yang L; Fang H; Jiang J; Sha Y; Zhong Z; Meng F
Drug Deliv Transl Res; 2022 Oct; 12(10):2527-2536. PubMed ID: 34802094
[TBL] [Abstract][Full Text] [Related]
50. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
51. Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.
Sonvico F; Barbieri S; Colombo P; Barocelli E; Mucchino C; Cantoni AM; Petronini PG; Rusca M; Carbognani P; Ampollini L
Eur J Pharm Sci; 2018 Oct; 123():89-97. PubMed ID: 30030099
[TBL] [Abstract][Full Text] [Related]
52. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
[TBL] [Abstract][Full Text] [Related]
53. Antimetabolites in the treatment of advanced pleural mesothelioma: a network meta-analysis of randomized clinical trials.
Tassinari D; Cherubini C; Tamburini E; Drudi F; Papi M; Fantini M; Lazzari-Agli L; Sartori S
J Chemother; 2017 Dec; 29(6):365-371. PubMed ID: 28697647
[TBL] [Abstract][Full Text] [Related]
54. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
Zhong A; Xiong X; Shi M; Xu H
Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
[TBL] [Abstract][Full Text] [Related]
55. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
56. Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.
Capelle H; Tummino C; Greillier L; Gouitaa M; Birnbaum J; Ausias N; Barlesi F; Montana M
J Clin Pharm Ther; 2018 Jun; 43(3):320-326. PubMed ID: 29092096
[TBL] [Abstract][Full Text] [Related]
57. Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
Nakano M; Kusaba H; Makiyama A; Ariyama H; Arita S; Oda H; Esaki T; Takayoshi K; Uchino K; Tamura S; Kumagai H; Iwama E; Shirakawa T; Mitsugi K; Takaishi S; Akashi K; Baba E
Anticancer Res; 2014 Jan; 34(1):215-20. PubMed ID: 24403465
[TBL] [Abstract][Full Text] [Related]
58. A new standard for malignant pleural mesothelioma.
Zauderer MG
Lancet; 2016 Apr; 387(10026):1352-1354. PubMed ID: 26719231
[No Abstract] [Full Text] [Related]
59. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
[TBL] [Abstract][Full Text] [Related]
60. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
Kondola S; Manners D; Nowak AK
Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]